February 2013 FDA Recall Drug by Watson Laboratories Inc (D-205-2013 - Failed Tablet/Capsule Specification; tablet breakage while pushing through the blister pack (dispenser) .)

This Class II drug recall was voluntarily initiated by Watson Laboratories Inc on February 13, 2013 for the product Drug. The FDA reported the reason for recall as failed tablet/capsule specification; tablet breakage while pushing through the blister pack (dispenser) .. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-205-2013

Reason for Recall
Failed Tablet/Capsule Specification; tablet breakage while pushing through the blister pack (dispenser) .
Initiated
02-13-2013
Reported
03-27-2013
Quantity
136,720 cartons

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Watson Laboratories Inc
ZARAH¿ Drospirenone/ Ethinyl Estradiol Tablets, 3.0 mg/0.03 mg, Rx only, 3 tablet dispensers, 28 tablets each, Manuf. by: Watson Laboratories, Inc., Corona, CA 92880. USA; Distributed by: Watson Pharma, Inc., Corona, CA 92880 USA. NDC 52544-981-31 Carton; NDC 52544-981-28

Batch or Lot Expiration Information

Lot# s: 401536AA/401536A; 401537AA/401537/A; 401538AA/401538/A; 406985AA/406985A; 432058AA/432058A; 512685AA/512685A